汇宇制药(688553) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was approximately ¥466.47 million, representing a year-on-year increase of 9.18%[3] - The net profit attributable to shareholders decreased by 11.49% to approximately ¥119.19 million, while the net profit after deducting non-recurring gains and losses fell by 17.37% to approximately ¥107.16 million[3] - Total operating revenue for Q1 2022 was ¥466,465,985.28, an increase of 9.2% compared to ¥427,252,220.09 in Q1 2021[19] - Net profit for Q1 2022 was ¥119,193,479.87, a decrease of 11.5% from ¥134,661,500.88 in Q1 2021[20] - The total profit for Q1 2022 was ¥124,827,762.12, a slight decrease from ¥150,076,189.08 in Q1 2021[19] - The company experienced a decrease in comprehensive income for Q1 2022, totaling ¥119,341,365.91 compared to ¥134,604,951.36 in Q1 2021[20] Cash Flow and Assets - The operating cash flow net amount decreased by 31.53% to approximately ¥97.69 million, indicating increased cash outflows from operating activities[3] - Cash flow from operating activities for Q1 2022 was ¥97,691,551.93, down 31.5% from ¥142,677,888.81 in Q1 2021[23] - Cash and cash equivalents were reported at RMB 1,241,257,455.04, compared to RMB 1,305,879,357.68 at the end of 2021, indicating a decrease of approximately 4.4%[13] - Cash and cash equivalents at the end of Q1 2022 were ¥1,241,257,455.04, compared to ¥88,801,271.55 at the end of Q1 2021[24] - The company reported a net cash outflow from investing activities of ¥112,150,912.90 in Q1 2022, an improvement from a net outflow of ¥425,184,108.70 in Q1 2021[24] Research and Development - Research and development expenses totaled approximately ¥67.93 million, accounting for 14.56% of revenue, an increase of 4.28 percentage points compared to the previous year[4] - Research and development expenses increased to ¥67,933,226.04 in Q1 2022, up 54.7% from ¥43,919,487.19 in Q1 2021[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,892, with no preferred shareholders[10] - The top shareholder, Ding Zhao, holds 26.93% of the shares, while Huang Qianyi holds 14.40%[10] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.23 billion, reflecting a 2.43% increase from the end of the previous year[4] - As of March 31, 2022, the total assets of Sichuan Huiyu Pharmaceutical Co., Ltd. amounted to RMB 4,229,828,277.25, an increase from RMB 4,129,505,041.77 at the end of 2021[15] - The company's current assets totaled RMB 3,232,282,663.44, slightly down from RMB 3,233,454,761.33 at the end of 2021[13] - Total liabilities decreased to RMB 551,990,058.38 from RMB 571,008,188.81, showing a reduction of approximately 3.1%[15] - The total equity attributable to shareholders rose to RMB 3,677,838,218.87 from RMB 3,558,496,852.96, marking an increase of about 3.3%[15] Other Financial Metrics - The weighted average return on net assets was 3.29%, a decrease of 13.16 percentage points compared to the previous year[3] - The company reported a significant increase in other receivables by 116.34% due to increased guarantee deposits during the reporting period[7] - The company experienced a 170.01% increase in non-operating expenses, attributed to increased donation expenditures and late fees[8] - The company's inventory increased to RMB 201,390,256.01 from RMB 178,867,240.51, reflecting a growth of about 12.6%[14] - The company's accounts receivable increased to RMB 13,111,021.14 from RMB 11,868,607.19, representing a growth of approximately 10.4%[13] - The non-current assets totaled RMB 997,545,613.81, up from RMB 896,050,280.44, indicating an increase of about 11.3%[14] - The company's other receivables rose to RMB 22,271,477.61 from RMB 10,294,820.81, reflecting a significant increase of approximately 116.5%[13] - The company reported a decrease in short-term borrowings to RMB 13,332,263.11 from RMB 13,664,102.35, a decline of about 2.4%[15] Operating Costs - Total operating costs for Q1 2022 were ¥351,833,639.57, up 24.6% from ¥282,348,411.44 in Q1 2021[19]